![](https://photos.idnfinancials.com/d/1600x900/Big%20Stock/bigstock-business-technology-and-peopl-82700837.jpg&nc)
Expanding to Australia, PYFA wraps up Probiotec acquisition
20 Jun 2024 09:48
PT Pyridam Farma Tbk’s (PYFA) steps in expanding the market to Australia is now materialised after acquiring the entire shares of Probiotic Limited, Australia.
20 Jun 2024 09:48
PT Pyridam Farma Tbk’s (PYFA) steps in expanding the market to Australia is now materialised after acquiring the entire shares of Probiotic Limited, Australia.
11 Jun 2024 17:31
PT Darya-Varia Laboratoria Tbk (DVLA) is reportedly preparing capital expenditure (capex) budget worth IDR 209 billion for 2024, which will mostly be allocated for expansion.
11 Jun 2024 16:00
PT Darya-Varia Laboratoria Tbk (DVLA) sets up IDR 65 per share for the final dividend of the fiscal year (FY) 2023, totalling IDR 72.8 billion, which will be taken out of its current year’s net profit in 2023.
15 Mar 2024 09:55
The performance of PT Pyridam Farma Tbk (PYFA) declined throughout 2023 compared to 2022.
27 Jul 2023 15:58
Although its profit went down by almost 30% in the first half of 2023, PT Phapros Tbk (PEHA) managed to record an increase in brand-name drugs sales.
08 Jun 2023 17:33
PT Phapros Tbk (PEHA), a pharmaceutical product manufacturer, readies dividend of IDR 11.2 billion that will be taken out of its net profit in 2022.
02 May 2023 18:03
PT Phapros Tbk (PEHA) posted growth in sales of ethical drugs, namely branded prescription drugs, up to 8.9% year-on-year (yoy) at the end of the first quarter of 2023
28 Apr 2023 11:11
PT Industri Jamu dan Farmasi Sido Muncul Tbk (SIDO) collected IDR 907.30 billion of revenue and IDR 300.237 billion of profit in Q1 2023.
06 Apr 2023 18:05
PT Pyridam Farma Tbk (PYFA), a pharmaceutical company, gained IDR 275.47 billion of net profit in 2022, proliferating 4,928% year-on-year (yoy) from IDR 5.47 billion in 2021.
10 Feb 2023 10:24
The performance of PT Industri Jamu dan Farmasi Sido Muncul Tbk (SIDO) was corrected in 2022 as the public’s purchase power weakened.